Assessment of effect of CYP3A inhibition, CYP induction, OATP1B inhibition, and high‐fat meal on pharmacokinetics of the JAK1 inhibitor upadacitinib

Por Mohamed, Mohamed‐Eslam F., Jungerwirth, Steven, Asatryan, Armen, Jiang, Ping, Othman, Ahmed A.
Publicado no Br J Clin Pharmacol (2017)

A Phase IIb Study of ABT‐494, a Selective JAK‐1 Inhibitor, in Patients With Rheumatoid Arthritis and an Inadequate Response to Anti–Tumor Necrosis Factor Therapy

Por Kremer, Joel M., Emery, Paul, Camp, Heidi S., Friedman, Alan, Wang, Li, Othman, Ahmed A., Khan, Nasser, Pangan, Aileen L., Jungerwirth, Steven, Keystone, Edward C.
Publicado no Arthritis Rheumatol (2016)

Efficacy and Safety of ABT‐494, a Selective JAK‐1 Inhibitor, in a Phase IIb Study in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate

Por Genovese, Mark C., Smolen, Josef S., Weinblatt, Michael E., Burmester, Gerd R., Meerwein, Sebastian, Camp, Heidi S., Wang, Li, Othman, Ahmed A., Khan, Nasser, Pangan, Aileen L., Jungerwirth, Steven
Publicado no Arthritis Rheumatol (2016)

Comparison of Intravenous/Oral Ciprofloxacin Plus Metronidazole Versus Piperacillin/Tazobactam in the Treatment of Complicated Intraabdominal Infections

Por Cohn, Stephen M., Lipsett, Pamela A., Buchman, Timothy G., Cheadle, William G., Milsom, Jeffery W., O’Marro, Steven, Yellin, Albert E., Jungerwirth, Steven, Rochefort, Estela V., Haverstock, Daniel C., Kowalsky, Steven F.
Publicado em 2000